Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.

[1]  D. Tziakas,et al.  Angiotensin Receptor Neprilysin Inhibitors—2019 Update , 2020, Cardiovascular Drugs and Therapy.

[2]  K. Anstrom,et al.  Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial. , 2020, Circulation.

[3]  P. Ponikowski,et al.  Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. , 2020, The New England journal of medicine.

[4]  M. Emdin,et al.  Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies , 2019, European journal of preventive cardiology.

[5]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[6]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[7]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[8]  S. Anderson,et al.  Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? , 2018, Heart.

[9]  F. Fernández‐Avilés,et al.  Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial , 2017, European heart journal.

[10]  M. Metra,et al.  Heart failure , 2017, The Lancet.

[11]  S. Solomon,et al.  The effects of sacubitril/valsartan on coronary outcomes in PARADIGM‐HF , 2017, American heart journal.

[12]  P. Ponikowski,et al.  Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure , 2017, The New England journal of medicine.

[13]  Sanjiv J. Shah,et al.  Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.

[14]  S. Solomon,et al.  LOW URINARY CGMP/BNP RATIO IS ASSOCIATED WITH WORSE OUTCOMES IN HEART FAILURE BUT IS INCREASED BY TREATMENT WITH SACUBITRIL/VALSARTAN: AN ANALYSIS OF PARADIGM-HF , 2017 .

[15]  D. Kass,et al.  Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease. , 2016, Handbook of experimental pharmacology.

[16]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[17]  S. Solomon,et al.  Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy , 2016, Circulation. Heart failure.

[18]  Akshay S. Desai,et al.  Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.

[19]  M. Volpe,et al.  The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment , 2015, Clinical science.

[20]  Gabriel A. Koepp,et al.  Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. , 2015, The New England journal of medicine.

[21]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[22]  T. Kume,et al.  Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. , 2015, Journal of cardiac failure.

[23]  Hyun-Jai Cho,et al.  PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. , 2015, American heart journal.

[24]  P. Kruzliak,et al.  Mechanisms of renal hyporesponsiveness to BNP in heart failure. , 2015, Canadian journal of physiology and pharmacology.

[25]  S. Solomon,et al.  Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. , 2014, JACC. Heart failure.

[26]  A. Lenzi,et al.  Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials , 2014, BMC Medicine.

[27]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[28]  S. Rosenkranz,et al.  Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1) , 2014, Chest.

[29]  Fei Li,et al.  PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. , 2014, International journal of cardiology.

[30]  T. Nakata,et al.  Evaluation of cardiac sympathetic nerve activity and aldosterone suppression in patients with acute decompensated heart failure on treatment containing intravenous atrial natriuretic peptide , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  J. Brugts,et al.  Impact of Intravenous Nitroglycerin in the Management of Acute Decompensated Heart Failure , 2014, Current Heart Failure Reports.

[32]  S. Rosenkranz,et al.  Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study , 2013 .

[33]  H. Ghofrani,et al.  Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study , 2013, Circulation.

[34]  C. Yancy,et al.  Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. , 2013, JACC. Heart failure.

[35]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[36]  G. Filippatos,et al.  Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes , 2012, European journal of heart failure.

[37]  L. Deckelbaum,et al.  Effect of nesiritide in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[38]  E. Herzog,et al.  Effect of Adding Nitroglycerin to Early Diuretic Therapy on the Morbidity and Mortality of Patients with Chronic Kidney Disease Presenting with Acute Decompensated Heart Failure , 2011, Hospital practice.

[39]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[40]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[41]  N. Dhalla,et al.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. , 2010, Experimental and clinical cardiology.

[42]  D. DeMets,et al.  Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials , 2009, European heart journal.

[43]  D. Kass,et al.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.

[44]  M. Guazzi.  Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure , 2008, Circulation. Heart failure.

[45]  T. Yoshikawa,et al.  Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[46]  Manuela Zaccolo,et al.  of in The Role of the in the A Molecular for Generating cAMP and cGMP Signaling Cross-Talk Role of Phosphodiesterases and Implications for Cardiac Pathophysiology , 2007 .

[47]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[48]  Alan S Maisel,et al.  Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. , 2005, American heart journal.

[49]  P. W. Leeuw,et al.  Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology , 2005, Fundamental & clinical pharmacology.

[50]  E. Topol.  Nesiritide - not verified. , 2005, The New England journal of medicine.

[51]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[52]  E. Walters,et al.  Phosphodiesterase 5 inhibitors for pulmonary hypertension , 2004 .

[53]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[54]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[55]  R. Califf,et al.  Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.

[56]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[57]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[58]  M. Cuffe.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. , 2002, JAMA.

[59]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[60]  C. Yancy.  Heart failure in African Americans: A cardiovascular enigma , 2000 .

[61]  Z. Vered,et al.  High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. , 2000, Journal of the American College of Cardiology.

[62]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[63]  N. Marsh,et al.  A Short History Of Nitroglycerine And Nitric Oxide In Pharmacology And Physiology , 2000, Clinical and experimental pharmacology & physiology.

[64]  J. Mckenney,et al.  A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. , 1999, American heart journal.

[65]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[66]  J. McMurray,et al.  Placebo‐controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure , 1999, European journal of heart failure.

[67]  Y. Moshkovitz,et al.  Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema , 1998, The Lancet.

[68]  C. Lang,et al.  Vasodilation in black Americans: Attenuated nitric oxide‐mediated responses , 1997, Clinical pharmacology and therapeutics.

[69]  V. Smith,et al.  Effect of African-American race and hypertensive left ventricular hypertrophy on coronary vascular reactivity and endothelial function. , 1997, Hypertension.

[70]  D. Heitjan,et al.  Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.

[71]  M. Kinoshita,et al.  Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. , 1993, Circulation.

[72]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[73]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[74]  H. Herrmann,et al.  Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.

[75]  J. Cohn,et al.  Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. , 1990, The American journal of cardiology.

[76]  R. Schlant,et al.  A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. , 1989, The New England journal of medicine.

[77]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[78]  R. Gillum.  Pathophysiology of Hypertension in Blacks and Whites: A Review of the Basis of Racial Blood Pressure Differences , 1979, Hypertension.